Investor Type | Firm |
Type of Fund | Venture Capital Fund |
Industries | Medical Devices (& Hospital Services) |
Stages | Early Stage, Expansion, Later Stage, Special Situations |
Investing | United States |
Investment Range | $2,000,000 - $20,000,000 |
Assets Under Management | $425,000,000 |
Montreux Equity Partners is a venture capital fund based in San Francisco, California, with an address at Four Embarcadero Center, Suite 3720, San Francisco, California, 94111, United States. They are a specialized investor that primarily focuses on the medical devices and hospital services sectors. With an expertise in equity investments, Montreux Equity Partners dedicates its efforts to invest in high-growth, commercial-stage companies that are leading their respective categories through innovative products, technologies, and services. Their investment approach and thesis hinge on the belief that they can effectively accelerate the scale of businesses they partner with. The fund has assets under management worth approximately $425 million and entertains an investment range from a minimum of $2 million to a maximum of $20 million. They prefer to engage in various stages of a company's life cycle, including early-stage, expansion, later stage, and special situations, allowing them a flexible spectrum of investment opportunities. By providing strategic growth investments and fostering mergers like the one between Kareo and PatientPop to form Tebra—a technology company aimed at modernizing healthcare practices—they demonstrate a commitment to not only funding but actively contributing to the success and innovation of their portfolio companies. Montreux's distinction lies in their deep industry expertise and their hands-on approach to collaborating with the companies in which they invest. Their latest news, including strategic growth investments and significant mergers within their portfolio, reflects their active role in creating synergies and scaling businesses that can bring transformative changes to the healthcare ecosystem.